<DOC>
	<DOC>NCT02418754</DOC>
	<brief_summary>The primary objective of the study is to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in patients with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monotherapy.</brief_summary>
	<brief_title>Study of Intravitreal REGN2176-3 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Key 1. Men or women â‰¥50 years of age 2. Active subfoveal CNV secondary to AMD as evidenced by FA in the study eye, as determined by the reading center, including juxtafoveal lesions that affect the fovea 3. BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye at the screening visit 4. Provide signed informed consent Key 1. Any prior treatment with antiVEGF treatment in the study eye 2. Any prior treatment (ie, systemic or ocular treatment) with PDGF or PDGFR inhibitors 3. Dense fibrotic scar or atrophy in the study eye involving the center of the fovea 4. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye 5. Prior vitrectomy in the study eye 6. Any history of macular hole of stage 2 and above in the study eye 7. Any intraocular or periocular surgery within 3 months of day 1 in the study eye, except lid surgery 8. History of corneal transplant in the study eye 9. Evidence of diabetic retinopathy or diabetic macular edema in either eye 10. Positive serum human chorionic gonadotropin/urine pregnancy test at the screening or baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>